Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Deerfield, IL, -- May 13, 2005, Astellas Pharma US, Inc. announced today the launch and availability of their newest systemic anti-fungal agent MYCAMINETM (micafungin sodium) for Injection to...
Read more about Anti-fungal Agent MYCAMINETM Available to Physicians
Japan, April 11, 2005 - Astellas Pharma Inc. ("Astellas") today announced that the Company obtained an approval from the Ministry of Health, Labor and Welfare (MHLW) for the immunosuppressant...
Read more about Prograf ® Is Approved For Additional Indication of Rheumatoid Arthritis
April 1st, 2005 Astellas Pharma Inc. ("Astellas"), today announced that the Company, headquartered in Tokyo, Japan, was created through the merger of Yamanouchi Pharmaceutical Co., Ltd....
Read more about Astellas Pharma Start Today As A New Star in the World Pharmaceutical Industry
Follow us
